论文部分内容阅读
目的分析益生菌治疗炎症性肠病的临床疗效。方法 32例炎症性肠病患者,采用随机数字表法分为观察组和对照组,各16例。对照组采用常规治疗,观察组使用常规治疗联合益生菌治疗方式,比较两组临床效果。结果观察组总有效率为81.25%,明显高于对照组的62.50%,差异具有统计学意义(P<0.05)。两组不良反应发生情况比较差异无统计学意义(P>0.05)。结论在治疗炎症性肠病采用益生菌联合柳氮磺吡啶能够有效提高临床治疗效果,安全性良好,值得临床推广。
Objective To analyze the clinical efficacy of probiotics in the treatment of inflammatory bowel disease. Methods 32 cases of inflammatory bowel disease patients were divided into observation group and control group using random number table method, with 16 cases in each group. The control group was treated by conventional therapy. The observation group was treated with conventional treatment combined with probiotics, and the clinical effects were compared between the two groups. Results The total effective rate of observation group was 81.25%, which was significantly higher than that of control group (62.50%), the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The treatment of inflammatory bowel disease using probiotics combined with sulfasalazine can effectively improve the clinical treatment effect, good safety, worthy of clinical promotion.